Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor: Structure optimization and pharmacokinetics

Journal of Pharmacology and Experimental Therapeutics

Volumn 332, Issue 3, 2010, Pages 1136-1145

  Ridwan, Rahmawati ^a   Kiptoo, Paul ^a   Kobayashi, Naoki ^c   Weir, Scott ^d   Hughes, Michael ^d   Williams, Todd ^b   Soegianto, Rondang ^e   Siahaan, Teruna J ^a  

^a UNIVERSITY OF KANSAS   (United States)

^b UNIVERSITY OF KANSAS   (United States)

^c ASTELLAS PHARMA INC   (Japan)

^d UNIVERSITY OF KANSAS CANCER CENTER   (United States)

^e UNIVERSITY OF INDONESIA   (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOCAPROIC ACID; CD11A ANTIGEN [237-246]; EPITOPE; INTERCELLULAR ADHESION MOLECULE 1; MACROGOL 6000; MYELIN; PHOSPHATE BUFFERED SALINE; PROTEIN INHIBITOR; PROTEOLIPID BIFUNCTIONAL PEPTIDE INHIBITOR; PROTEOLIPID PROTEIN [139-515]; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; AREA UNDER THE CURVE; ARTICLE; CELL INTERACTION; COMPARATIVE STUDY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE SEVERITY; DRUG ACTIVITY; DRUG INHIBITION; DRUG PROTEIN BINDING; DRUG STRUCTURE; FEMALE; IN VIVO STUDY; MAJOR HISTOCOMPATIBILITY COMPLEX; MALE; MORBIDITY; MOUSE; MULTIPLE SCLEROSIS; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE;

ANAPHYLAXIS; ANIMALS; ANTIGENS, CD11; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; EPITOPES; FEMALE; INTERLEUKIN-17; MALE; MICE; MYELIN PROTEOLIPID PROTEIN; OLIGOPEPTIDES; PEPTIDE FRAGMENTS; RATS; RATS, SPRAGUE-DAWLEY; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 77249151872     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.161109     Document Type: Article

References (36)

1. Alexander C, Kay AB, and Larche M (2002) Peptide-based vaccines in the treatment of specific allergy. Curr Drug Targets Inflamm Allergy 1:353-361.
2. Bielekova B, Goodwin B, Richert N, Cortese I, Kondo T, Afshar G, Gran B, Eaton J, Antel J, Frank JA, et al. (2000) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167-1175.
3. Bromley SK, Burack WR, Johnson KG, Somersalo K, Sims TN, Sumen C, Davis MM, Shaw AS, Allen PM, and Dustin ML (2001) The immunological synapse. Annu Rev Immunol 19:375-396.
4. Bromley SK and Dustin ML (2002) Stimulation of naive T-cell adhesion and immunological synapse formation by chemokine-dependent and -independent mechanisms. Immunology 106:289-298.
5. Dhodapkar MV, Steinman RM, Krasovsky J, Munz C, and Bhardwaj N (2001) Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med 193:233-238.
6. + T cells in experimental autoimmune encephalomyelitis. Am J Pathol 173:411-422.
7. Frauwirth KA and Thompson CB (2002) Activation and inhibition of lymphocytes by costimulation. J Clin Invest 109:295-299.
8. Grakoui A, Bromley SK, Sumen C, Davis MM, Shaw AS, Allen PM, and Dustin ML (1999) The immunological synapse: a molecular machine controlling T cell activation. Science 285:221-227.
9. Hedegaard CJ, Krakauer M, Bendtzen K, Lund H, Sellebjerg F, and Nielsen CH (2008) T helper cell type 1 (Th1), Th2, and Th17 responses to myelin basic protein and disease activity in multiple sclerosis. Immunology 125:161-169.
10. Huizinga R, Gerritsen W, Heijmans N, and Amor S (2008) Axonal loss and gray matter pathology as a direct result of autoimmunity to neurofilaments. Neurobiol Dis 32:461-470.
11. Johnson KP (1996) Management of relapsing/remitting multiple sclerosis with copolymer 1 (Copaxone). Mult Scler 1:325-326.
12. Kappos L, Bates D, Hartung HP, Havrdova E, Miller D, Polman CH, Ravnborg M, Hauser SL, Rudick RA, Weiner HL, et al. (2007) Natalizumab treatment for multiple sclerosis: recommendations for patient selection and monitoring. Lancet Neurol 6:431-441.
13. Kappos L, Comi G, Panitch H, Oger J, Antel J, Conlon P, and Steinman L (2000) Induction of a nonencephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial. The Altered Peptide Ligand in Relapsing MS Study Group. Nat Med 6:1176-1182.
14. Kobayashi N, Kiptoo P, Kobayashi H, Ridwan R, Brocke S, and Siahaan TJ (2008) Prophylactic and therapeutic suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. Clin Immunol 129:69-79.
15. Kobayashi N, Kobayashi H, Gu L, Malefyt T, and Siahaan TJ (2007) Antigen-specific suppression of experimental autoimmune encephalomyelitis by a novel bifunctional peptide inhibitor. J Pharmacol Exp Ther 322:879-886.
16. Korn T, Bettelli E, Oukka M, and Kuchroo VK (2009) IL-17 and Th17 cells. Annu Rev Immunol 27:485-517.
17. Kuchroo VK, Greer JM, Kaul D, Ishioka G, Franco A, Sette A, Sobel RA, and Lees MB (1994) A single TCR antagonist peptide inhibits experimental allergic encephalomyelitis mediated by a diverse T cell repertoire. J Immunol 153:3326-3336.
18. Langer-Gould A, Atlas SW, Green AJ, Bollen AW, and Pelletier D (2005) Progressive multifocal leukoencephalopathy in a patient treated with natalizumab. N Engl J Med 353:375-381.
19. Larche M and Wraith DC (2005) Peptide-based therapeutic vaccines for allergic and autoimmune diseases. Nat Med 11:S69-S76.
20. Lee KH, Holdorf AD, Dustin ML, Chan AC, Allen PM, and Shaw AS (2002) T cell receptor signaling precedes immunological synapse formation. Science 295:1539-1542.
21. Leech MD, Chung CY, Culshaw A, and Anderton SM (2007) Peptide-based immunotherapy of experimental autoimmune encephalomyelitis without anaphylaxis. Eur J Immunol 37:3576-3581.
22. Lock C, Hermans G, Pedotti R, Brendolan A, Schadt E, Garren H, Langer-Gould A, Strober S, Cannella B, Allard J, et al. (2002) Gene-microarray analysis of multiple sclerosis lesions yields new targets validated in autoimmune encephalomyelitis. Nat Med 8:500-508.
23. + T cells. Immunol Res 36:275-282.
24. Matusevicius D, Kivisakk P, He B, Kostulas N, Ozenci V, Fredrikson S, and Link H (1999) Interleukin-17 mRNA expression in blood and CSF mononuclear cells is augmented in multiple sclerosis. Mult Scler 5:101-104.
25. Menges M, Rossner S, Voigtlander C, Schindler H, Kukutsch NA, Bogdan C, Erb K, Schuler G, and Lutz MB (2002) Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J Exp Med 195:15-21.
26. Metzler B, Anderton SM, Manickasingham SP, and Wraith DC (2000) Kinetics of peptide uptake and tissue distribution following a single intranasal dose of peptide. Immunol Invest 29:61-70.
27. Monks CR, Freiberg BA, Kupfer H, Sciaky N, and Kupfer A (1998) Three-dimensional segregation of supramolecular activation clusters in T cells. Nature 395:82-86.
28. Morishima N, Mizoguchi I, Takeda K, Mizuguchi J, and Yoshimoto T (2009) TGF-β is necessary for induction of IL-23R and Th17 differentiation by IL-6 and IL-23. Biochem BioPhys Res Commun 386:105-110.
29. Murray JS, Oney S, Page JE, Kratochvil-Stava A, Hu Y, Makagiansar IT, Brown JC, Kobayashi N, and Siahaan TJ (2007) Suppression of type 1 diabetes in NOD mice by bifunctional peptide inhibitor: modulation of the immunological synapse formation. Chem Biol Drug Des 70:227-236.
30. Rueda F, Hygino LC Jr, Domingues RC, Vasconcelos CC, Papais-Alvarenga RM, and Gasparetto EL (2008) Diffusion tensor MR imaging evaluation of the corpus callosum of patients with multiple sclerosis. Arq Neuropsiquiatr 66: 449-453.
31. + T cells to induce experimental autoimmune encephalomyelitis by a nonencephalitogenic myelin variant antigen. J Immunol 180:4451-4457.
32. Santambrogio L, Sato AK, Fischer FR, Dorf ME, and Stern LJ (1999) Abundant empty class II MHC molecules on the surface of immature dendritic cells. Proc Natl Acad Sci U S A96:15050-15055.
33. Schaub M, Issazadeh S, Stadlbauer TH, Peach R, Sayegh MH, and Khoury SJ (1999) Costimulatory signal blockade in murine relapsing experimental autoimmune encephalomyelitis. J Neuroimmunol 96:158-166.
34. Shen CR, Youssef AR, Devine A, Bowie L, Hall AM, Wraith DC, Elson CJ, and Barker RN (2003) Peptides containing a dominant T-cell epitope from red cell band 3 have in vivo immunomodulatory properties in NZB mice with autoimmune hemolytic anemia. Blood 102:3800-3806.
35. Smith CE, Eagar TN, Strominger JL, and Miller SD (2005) Differential induction of IgE-mediated anaphylaxis after soluble vs. cell-bound tolerogenic peptide therapy of autoimmune encephalomyelitis. Proc Natl Acad Sci U S A102:9595-9600.
36. + T cell subsets in the experimental autoimmune encephalomyelitis, a mouse model of multiple sclerosis. Tohoku J Exp Med 213:329-339.